Psychiatric Bulletin (2003) 27: 93-95. doi: 10.1192/pb.27.3.93
© 2003 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Thomas, A.
Right arrow Articles by Taylor, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Thomas, A.
Right arrow Articles by Taylor, D.
Psychiatric Bulletin (2003) 27: 93-95
© 2003 The Royal College of Psychiatrists

Evaluating the relationship of high-dose venlafaxine prescribing to treatment-resistant depression

Arwel Thomas, Clinical Pharmacist and David Taylor, Chief Pharmacist

Pharmacy Department, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK

Declaration of interest

A. T. — None. D. T. has previously received consultancy fees from Wyeth, whose interests may be affected by publication of this paper.

AIMS AND METHOD

Prescribing of venlafaxine in The South London and Maudsley NHS Trust was found to account for over 50% of the antidepressant costs, but only 15% of the prescriptions. There is evidence to suggest that higher doses of venlafaxine may be effective in treating treatment-refractory depression. We aimed to discover if higher doses of venlafaxine used in the trust were related to prior failure to respond to antidepressant treatment. Hospital in-patients being treated with venlafaxine during a 1-week period in October 2001 were identified and case notes were reviewed to determine patient demographic data and prior history of antidepressant therapy.

RESULTS

There were 38 patients identified as being prescribed venlafaxine (18 of whom had a primary diagnosis of depression). Twenty-five were classed as non-treatment-resistant and 13 were classed as treatment-resistant. Doses of venlafaxine were statistically significantly higher in patients considered treatment-resistant (245 mg v. 180 mg daily, P=0.03). All other recorded patient characteristics were similar.

CLINICAL IMPLICATIONS

Higher doses of venlafaxine were prescribed to patients who were retrospectively defined as treatment-refractory. Further studies should address the reasons for this prescribing practice.




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
D. Taylor and J R. Scott
Volte-faceon venlafaxine - reasons and reflections
J Psychopharmacol, September 1, 2006; 20(5): 597 - 601.
[PDF]